HLA-DRB1 and myeloid sarcoma: We then performed mediation analysis using the causal inference test (CIT) method [23] to test for causality between the HLA-DRB1 risk haplotype (casual factor), DMR methylation (mediator), and clinical definite MS (CDMS) as the phenotype.